Related Experiment Video
Updated: May 8, 2026
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of
Mei-Hsuan Lee1,2,3, Maria Stepanova1,4, Michael Estep1,2
1The Global NASH/MASH Council (GNC), Washington, DC, USA.
Summary
Genetic risk for liver fibrosis in metabolic dysfunction-associated steatotic liver disease (MASLD) varies by clinical setting. The PNPLA3 gene variant shows stronger associations with fibrosis in tertiary-care patients compared to community-based individuals.
Area of Science:
- Hepatology
- Genetics
- Metabolic Diseases
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global health concern.
- Genetic factors influence MASLD progression, but their impact on fibrosis severity across different clinical settings is not fully understood.
Purpose of the Study:
- To investigate the association between key MASLD-related genetic variants and liver fibrosis severity.
- To compare these genetic associations in community-based versus tertiary-care hepatology populations.
Main Methods:
- Cross-sectional analysis of 6446 MASLD patients from community and tertiary-care cohorts.
- Fibrosis severity assessed using the FIB-4 index.
- Logistic regression used to evaluate associations of PNPLA3, TM6SF2, and MBOAT7 variants with fibrosis.
Main Results:
- Advanced fibrosis was more prevalent in the tertiary-care group.
- PNPLA3 rs738409 showed consistent associations with fibrosis in both settings, with significantly stronger effects in tertiary-care patients.
- TM6SF2 rs58542926 had modest associations in the community group; MBOAT7 rs641738 showed no association.
Conclusions:
- Genetic associations with MASLD fibrosis are context-dependent.
- Clinical and metabolic factors in tertiary-care settings may amplify the effect of genetic variants like PNPLA3 on liver fibrosis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...